Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (946)

« Back to Publications

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Mukhopadhyay ES. et al, (2026), Vaccine, 69

Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM

Mukhopadhyay ES. et al, (2025), Vaccine, 68, 127897 - 127897

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.

Anywaine Z. et al, (2025), The Lancet. Infectious diseases

Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice

Mukhopadhyay E. et al, (2025), Frontiers in Immunology, 16

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

McDaniel JR. et al, (2025), The Journal of experimental medicine, 222

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial.

Dabira ED. et al, (2025), Trials, 26

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Kibwana E. et al, (2025), Frontiers in Immunology, 16

Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial

Bundi C. et al, (2025), Frontiers in Immunology, 16

Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot

Guyon R. et al, (2025), Science Translational Medicine, 17

Identification of cross-stage, cross-species malaria CD8+ T cell antigens.

Barbosa CRR. et al, (2025), Res Sq

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

Dold C. et al, (2025), Science Translational Medicine, 17

A roadmap of priority evidence gaps for the co-implementation of malaria vaccines and perennial malaria chemoprevention.

Grant J. and Perennial Malaria Chemoprevention (PMC) community of practice sub-group on the co-implementation of malaria vaccines and PMC ., (2025), Malaria journal, 24

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100868 - 100868

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100867 - 100867

Load More

1
2
3
4
5
6
7
...
»